Company: GRRR
Filing Date: 2025-07-02
Form Type: 424B5
Source: 0001213900-25-060827
Chunk: 51

Company: Gorilla Technology Group Inc.
Filing Date: 2025-07-02
Form: 424B5
Chunk 51
---
 practice, we may                                   
 not, comply with certain Nasdaq rules requiring Gorilla’s independent directors to meet in regularly scheduled                 
 executive sessions at which only independent directors are present. Gorilla will follow Cayman Islands practice which does not 
 require independent directors to meet regularly in executive sessions separate from the full board of directors.               |

| ● | Proxy Statements. We are not required to and, in reliance on home country practice, we may                              
 not, comply with certain Nasdaq rules regarding the provision of proxy statements for general meetings of shareholders. 
 Gorilla will follow Cayman Islands practice which does not impose a regulatory regime for the solicitation of proxies.  |

| ● | Shareholder Approval. Gorilla is not required to and, in reliance on home country practice,                                    
 it does not intend to, comply with certain Nasdaq rules regarding shareholder approval for certain issuances of securities     
 under Nasdaq Rule 5635. In accordance with the provisions of Gorilla’s Amended and Restated Memorandum and                     
 Articles of Association, Gorilla’s board of directors is authorized to issue securities, including ordinary shares, preference 
 shares, warrants and convertible notes.                                                                                        |

Risk Factors Investing in our securities entails a high degree of risk as more fully described in the “Risk Factors” section of this prospectus beginning on page 5. You should carefully consider such risks before deciding to invest in our securities. Recent Developments On August 17, 2023, we entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., referred to as the agent. In accordance with the terms of the Sales Agreement, we may issue and sell, from time to time, ordinary shares, through the agent, acting as agent or principal. Sales of ordinary shares, if any, will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act. Under the Sales Agreement, the agent is not required to sell any specific amount but will act as our sales agent using commercially reasonable efforts consistent with each of their normal trading and sales practices, on mutually agreed terms between the agent and us. This prospectus is intended to cover, among others, the offering, issuance and sale by us of ordinary shares in at the market offerings as contemplated by the Sales Agreement, with further details being specified in a prospectus relating to the Sales Agreement.

<div align='center'>4

RISK FACTORS</div>

An investment in our securities
invol